Abstract 1434P
Background
The spatial architecture of B and T cells in the tumor microenvironment (TME) is known to be associated with treatment response in cancer patients. However, more complex spatial statistics to characterize the interaction of more than two immune cell types could further inform our understanding of tumor response to immunotherapy (IO). In this work we sought to evaluate quantitative metrics of higher order spatial relationships between multiple (>2) cell types to better characterize and predict overall survival (OS) in NSCLC patients.
Methods
The study included quantitative immunofluorescence images of pre-IO tumor biopsy specimen of 135 NSCLC patients from five centers with OS information. To predict OS, a set of 223 image features that characterize the spatial interplay of different cell types (CD4+, CD20+, CD8+, tumor, and stroma) in the TME were extracted. First, every nucleus belonging to each immune cell family was detected using an image analysis program (MATLAB) to identify the cell’s expression, subsequently the cell coordinates were recorded. The algorithm then identifies each triplet of distinct cells in proximity of each other to form spatial triangles. Features relating to the density, neighborhood, and proximity of nuclei were subsequently extracted. A risk score (RS) was then computed for each patient using the least absolute shrinkage and selection operator. To predict OS, the Cox regression model was trained on 100 patients (St) and validated on 35 patients (Sv). The discriminative ability of the features was assessed using Kaplan-Meier and log-rank tests.
Results
The RS was significantly associated with OS in both St (HR: 1.76; 95% CI = 1.09 - 2.85; P = .02), and Sv (HR: 2.8; 95% CI= 1.18–6.68; P=.01). RS based risk stratification showed greater accumulation of tumor, CD4 T cells, and CD20 B cells in very close proximity of each other in low-risk patients, compared to high-risk patients.
Conclusions
Machine learning derived features describing the higher order spatial relationships between tumor, CD20 B cells, and CD4 T cells were found to be associated with OS in NSCLC patients treated with IO. Additional, independent multi-site validation of these findings is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
K. Schalper: Financial Interests, Speaker, Consultant, Advisor: Agenus, Ariagen, AstraZeneca, Bristol Myers Squibb , Clinica Alemana de Santiago, Genmab, Merck Sharp and Dohme, OnCusp Therapeutics, Repertoir Therapeutics, Takeda Oncology; Financial Interests, Institutional, Research Grant: Akoya Biosciences, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb , Eli Lilly and Company , Merck Sharp and Dohme, Navigate Biopharma, Pierre-Fabre, Ribon Therapeutics, Surface Oncology, Takeda Oncology, Tesaro, Inc.; Financial Interests, Advisory Board: EMD Serono, Shattuck Labs; Financial Interests, Research Grant: Moderna Inc. A. Madabhushi: Financial Interests, Personal, Advisory Board, Serve on SAB and consult: SimbioSys; Financial Interests, Personal, Advisory Board: Aiforia, Picture Health; Financial Interests, Personal, Full or part-time Employment: Picture Health; Financial Interests, Personal, Ownership Interest: Picture Health, Elucid Bioimaging, Inspirata Inc; Financial Interests, Personal, Royalties: Picture Health, Elucid Bioimaging; Financial Interests, Institutional, Funding: AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly. All other authors have declared no conflicts of interest.
Resources from the same session
1368P - LUMINATE 102: A real-world study on biomarker testing rates among patients with non-small cell lung cancer (NSCLC) across lines of therapy
Presenter: Charu Aggarwal
Session: Poster session 20
1369P - BrigAlec study: Focus on alectinib efficacy after brigatinib exposure in BrigALK2 study (GFPC 02-2019)
Presenter: Renaud Descourt
Session: Poster session 20
1370P - Efficacy and safety of ensartinib in ALK-positive non-small cell lung cancer patients with brain metastases: A multicenter, open-label, single-arm, phase II study
Presenter: Jianhua Chang
Session: Poster session 20
1371P - First-line alectinib vs. brigatinib in advanced metastatic NSCLC with ALK rearrangement: Real-world data
Presenter: Young Kyung Jeon
Session: Poster session 20
1372P - Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial
Presenter: Ben Solomon
Session: Poster session 20
1373P - Efficacy and safety of taletrectinib in patients (Pts) with ROS1+ non-small cell lung cancer (NSCLC): Interim analysis of global TRUST-II study
Presenter: Maurice Pérol
Session: Poster session 20
1374P - Survival and therapy analysis of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients
Presenter: Moritz Glaser
Session: Poster session 20
1375P - Beamion Lung 1, an ongoing phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients (pts) with advanced solid tumors with HER2 aberrations: Latest data
Presenter: Frans Opdam
Session: Poster session 20
1377P - Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity
Presenter: Xiuning Le
Session: Poster session 20
1378P - Efficacy and safety of tunlametinib (HL-085) combined with vemurafenib in patients with advanced BRAF V600-mutated solid tumors: A multicenter, phase I study
Presenter: Yuan-Kai Shi
Session: Poster session 20